URMC Neurology Research

Movement & Inherited Neurological Disorders Unit (MIND)

Scope of Research: Clinical Research and Experimental Therapeutics

Goals are to initiate, coordinate and carry out clinical trials and epidemiological studies related to movement disorders, inherited and acquired neurological disorders. Key element is training program in Experimental Therapeutics for fellows.

References
Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, Elm J. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69 (4):342-7.

Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott M. The Relationship between CAG Repeat Length and Clinical Progression in Huntington's disease. Movement Disorders. 2008 Jul 15; 23(9):1223-7.

Ravina B, MD, Tanner C, DiEuliis D, Eberly S, Flagg E, Galpern W, Fahn S, Goetz C, Grate S, Kurlan R, Lang A, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I, and the Parkinson Study Group LABS-PD Investigators.  A Longitudinal Program for Biomarker Development in Parkinson disease: A Feasibility Study.  In press, Movement Disorders

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson’s disease in the most populous nations, 2005 – 2030. Neurology 2007; 68:384-6.

Dorsey ER, Vitticore P, de Roulet J, Thompson JP, Carrasco M, Johnston SC, Holloway RG, Moses H. Financial anatomy of neuroscience research. Ann Neurol 2006; 60:652-9.

Schifitto,G.; Zhang,J.; Evans,S.R.; Sacktor,N.; Simpson,D.; Millar,L.L.; Hung,V.L.; Miller,E.N.; Smith,E.; Ellis,R.J.; Valcour,V.; Singer,E.; Marra,C.M.; Kolson,D.; Weihe,J.; Remmel,R.; Katzenstein,D.; Clifford,D.B.; the,ACTG A.;. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment". Neurology 69 (2007): 1314-1321.

Schifitto,G.; Navia,B.A.; Yiannoutsos,C.T.; Marra,C.M.; Chang,L.; Ernst,T.; Jarvik,J.G.; Miller,E.N.; Singer,E.J.; Ellis,R.J.; Kolson,D.L.; Simpson,D.; Nath,A.; Berger,J.; Shriver,S.L.; Millar,L.L.; Colquhoun,D.; Lenkinski,R.; Gonzalez,R.G.; Lipton,S.A.;. "Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study". AIDS 21 (2007): 1877-1886.

Biglan, KM, Holloway RG Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007 Jul 10;69(2):187-95.PMID: 17620552

Parkinson Study Group (Biglan KM, corresponding author). The Long Term Impact of Initiating Pramipexole versus Levodopa in Early Parkinson’s Disease. Archives of Neurology. 2009. 66(5):563-570.

Parkinson Study Group (Shoulson I, PI). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176-183, 1993.

Parkinson Study Group PRECEPT Investigators (Shoulson I, primary author). The mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson’s disease. Neurology 69:1480-1490, 2007.

Parkinson Study Group (Holloway R, primary author, Kieburtz K). Pramipexole vs. levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 2000;284:1931-1938.

The Parkinson Study Group (Fahn S, primary author, Kieburtz K, Steering Com). Levodopa and the progression of Parkinson’s disease. NEJM 2004;351:2498-508.

Bernard Ravina, M.D., MSCE Unit Chief
bernard_ravina@ctcc.rochester.edu
(585) 275-7430

Ira Shoulson, M.D., Director, Program in Experimental Therapeutics
(585) 275-2585